Human p21 (also known as WAF1, CIP1, or SDI1) is a dual inhibitor of cyclin dependent kinases (CDKs) and the replication factor PCNA, which plays a role as a downstream mediator of the cell-cycle arrest induced by the tumor suppressor p53. To determine whether inactivation of downstream targets of p53 might contribute to cellular transformation, we have examined the integrity of the p21 gene in 36 invasive ductal breast carcinomas. Direct sequence analysis of the polymerase chain reaction-amplified p21 gene revealed a C to T transition in codon 94 that caused the substitution of a tryptophan for an arginine in a tumor specimen. This mutation was not detected in normal DNA extracted from the same patient nor in a polymerase chain reaction-restriction fragment length polymorphism of 50 unrelated individuals, indicating that it corresponds to a tumor-specific alteration. Functional analysis of the p21 R94W protein produced in different eukaryotic and prokaryotic expression systems revealed that this mutation impaired the ability of p21 to inhibit CDKs. By contrast, the R94W mutant was unaltered in its ability to promote cyclin-CDK association as well as in its ability to bind proliferating cell nuclear antigen, thus leaving its putative functions as kinase activator or as inhibitor of replicative DNA synthesis intact. On the basis of these functional analysis, we propose that the Arg residue at position 94 is important for the CDK inhibitory role of p21.
Human p21 (also known as WAF1, CIP1, or SDI1) is a dual inhibitor of cyclin dependent kinases (CDKs) and the replication factor PCNA, which plays a role as a downstream mediator of the cell-cycle arrest induced by the tumor suppressor p53. To determine whether inactivation of downstream targets of p53 might contribute to cellular transformation, we have examined the integrity of the p21 gene in 36 invasive ductal breast carcinomas. Direct sequence analysis of the polymerase chain reaction-amplified p21 gene revealed a C to T transition in codon 94 that caused the substitution of a tryptophan for an arginine in a tumor specimen. This mutation was not detected in normal DNA extracted from the same patient nor in a polymerase chain reaction-restriction fragment length polymorphism of 50 unrelated individuals, indicating that it corresponds to a tumor-specific alteration. Functional analysis of the p21 R94W protein produced in different eukaryotic and prokaryotic expression systems revealed that this mutation impaired the ability of p21 to inhibit CDKs. By contrast, the R94W mutant was unaltered in its ability to promote cyclin-CDK association as well as in its ability to bind proliferating cell nuclear antigen, thus leaving its putative functions as kinase activator or as inhibitor of replicative DNA synthesis intact. On the basis of these functional analysis, we propose that the Arg residue at position 94 is important for the CDK inhibitory role of p21.
The control of cell proliferation in eukaryotes is a complex process involving the sequential activation and inactivation of a family of serine/threonine protein kinases known as cyclindependent kinases (CDKs) . 1 The activity of these enzymes is controlled by their association with a series of regulatory subunits called cyclins (Morgan, 1995; Pines, 1995) . In addition, recent studies from different groups have led to the identification of a family of proteins with ability to bind to the diverse cyclin-CDK complexes and to inhibit their activity (Peter and Herskowitz, 1994; Sherr and Roberts, 1995; Hirama and Koeffler, 1995) . At present, a total of seven negative regulators of the cell cycle have been isolated and characterized at the amino acid sequence level, being the one called p21 the first to be identified (Xiong et al., 1993a) . p21, also known as WAF1 (wild type p53 activated fragment-1) (El-Deiry et al., 1993) , CIP1 (cyclin-dependent kinases interacting protein-1) (Harper et al., 1993) , or SDI1 (senescent cell-derived inhibitor-1) (Noda et al. 1994) , is a nuclear arginine-rich protein that inhibits the activity of all CDKs, preventing phosphorylation of their corresponding substrates and blocking cell-cycle transition from G 1 to S phase.
The expression of the p21 gene is regulated by the tumor suppressor protein p53 (El-Deiry et al., 1993) , a transcription factor that controls the arrest of cell cycle progression at G 1 checkpoint in response to DNA damage, thus preventing replication of damaged templates while allowing appropriate DNA repair (Vogelstein and Kinzler, 1992; Ullrich et al., 1992; Levine, 1993; Cox and Lane, 1995) . A series of recent findings have reinforced the idea that p21 serves as a key effector of cell-cycle arrest pathways (El-Deiry et al., 1993 Michieli et al., 1994; Macleod et al., 1995) . Thus, introduction of wild type p21 into a number of different tumor cell lines caused growth suppression, whereas transfection with a p21 cDNA mutant directing the synthesis of a truncated protein, resulted in loss of the ability of p21 to suppress growth of these tumor cells in vitro. In addition, p21 expression has been found to be stimulated by DNA damage induced by ionizing radiation in cells with a wild type p53 gene but not in cells harboring deletions or missense mutations in the p53 gene. Finally, whole-body irradiation of normal and p53 (Ϫ/Ϫ) mice, caused a marked increase in the levels of p21 mRNA in most wild type tissues but not in p53 deficient tissues. However, and although these results indicate that p21 is an essential part of the p53-mediated growth arrest pathway elicited by DNA damage, p21 can be also regulated independently of p53 in several situations including normal tissue development and cellular differentiation in response to appropriate signals like TGF-␤, MyoD, phorbol esters, or retinoic acid Sheikh et al., 1994; Jiang et al., 1994; Halevy et al., 1995; Parker et al., 1995; Macleod et al., 1995; Li et al., 1995a) .
In addition to its well established role as a general CDK inhibitor, p21 also complexes in vitro with the proliferating cell nuclear antigen (PCNA), an essential DNA polymerase ␦ auxilliary factor that greatly enhances its processivity Flores-Rozas et al., 1994) . On the basis of these binding properties, it has been proposed that p21 can directly inhibit DNA replication in a way that appears to be independent of its cyclin-CDK inhibitory properties. Interestingly, p21 binding to PCNA results in the inhibition of the role of this auxilliary factor in DNA replication but not in nucleotide excision-repair, thus allowing growth-arrest while permitting active repair of damaged DNA Shivji et al., 1994) .
Taking into account this essential role of p21 as a downstream mediator of the cell cycle arrest induced by p53 as well as its direct role as an inhibitor of DNA replication, it is tempting to speculate that mutations in this gene might be involved in the development or progression of human cancers. In addition and because at present the precise mechanisms of inhibition of CDKs and PCNA interaction are not yet completely elucidated, functional analysis of putative p21 mutants could be important to define specific residues or protein domains that could be relevant for the biological activity of this protein. In this work, we show the identification of a p21 mutant present in a human breast carcinoma and characterized by the replacement of arginine at position 94 with a tryptophan residue. We have also performed a functional analysis of the mutant protein with the finding that the identified mutation impairs the ability of p21 to inhibit CDKs.
EXPERIMENTAL PROCEDURES
Materials-Human breast tumors were obtained from women who had undergone surgery for primary breast carcinoma. The samples were immediately frozen in liquid nitrogen and stored at Ϫ70°C until used. Oligonucleotides were synthesized by the phosphoramidite method in an Applied Biosystems DNA synthesizer (model 381 A) and used directly after synthesis. Restriction endonucleases and other reagents used for molecular cloning were from Boehringer Mannheim. Insect Sf9 cells were cultured in Grace's medium supplemented with 10% heat-inactivated fetal bovine serum, lactalbumin hydrolysate, and yeastolate ultrafiltrate at 27°C. Antibodies against p21, CDK2, and CDK6 were described earlier (Xiong et al., 1993a (Xiong et al., , 1993b Zhang et al., 1994) .
DNA Extraction and PCR Amplification-Genomic DNA was prepared from peripheral blood cells or from tumor biopsies from women with breast cancer as well as from peripheral blood cells of the general population. This genomic DNA was used as a substrate for amplification of the two coding exons of the p21 gene. Exon 2 of the p21 gene was amplified with oligonucleotides 5Ј-GCGCCATGTCAGAACCGGC and 5Ј-GAGAATCCTGGTCCCTTAC, and exon 3 was amplified with oligonucleotides 5Ј-GCCCCCCACTGTCTTCCT and 5Ј-GCGCTTCCAG-GACTGCAGG. PCR conditions for amplification consisted in a 10-min denaturalization step at 94°C (without adding enzyme) followed by 30 cycles of 30 s at 94°C, 30 s at 55°C, and 30 s at 72°C. 2 l of this PCR product were used for asymmetric PCR following the procedure previously described (Balbín et al., 1993) .
Nucleotide Sequence and PCR-Restriction Fragment Length Polymorphism Analysis-DNA fragments amplified by asymmetric PCR were sequenced by the dideoxy chain termination method (Sanger et al., 1977) using the Sequenase version 2.0 kit (U. S. Biochemical Corp.). The sequencing reactions were performed on both strands of the PCR products when mutations were detected. For PCR-restriction fragment length polymorphism analysis of amplified exon 2 of the human p21 gene, 10 -20-l portions were digested with ItaI and analyzed in a 2% agarose gel electrophoresis. After electrophoresis, DNA fragments were visualized by ethidium bromide staining.
Generation of Baculovirus Recombinants-Recombinant baculoviruses directing the expression of p21 protein or mutant p21 R94W as a fusion with glutathione S-transferase were generated by insertion of the wild type or mutant p21 cDNAs into the baculovirus transfer vector pAc-2T (Pharmingen) as described by the manufacturer. Expression of cyclin A-CDK2 and cyclin D1-CDK6 and preparation of kinase lysates were performed as described previously (Xiong et al., 1993a; Zhang et al., 1994) . GST-p21 or GST-p21 R94W were expressed in insect Sf9 cells,
35
S-labeled, and normalized by PhosphorImager analysis and by Western blotting with the p21 antiserum prior to use. The specificities of antibodies against the different cyclins and CDKs have been already reported (Xiong et al., 1993a (Xiong et al., , 1993b Zhang et al., 1994) .
Immunoprecipitation, Binding, and Kinase Assays-For p21 inhibition assays, increasing quantities of baculoviral lysates containing p21 were mixed with 5 l of insect cell lysates containing cyclin A-CDK2 or cyclin D1-CDK6 in a final volume of 30 l containing 10 mM Tris, pH 8.0, 10 mM MgCl 2 , and 1 mM EGTA. Mixtures were then incubated at 30°C for 30 min. For cyclin A-CDK2, reactions were diluted to 250 l with IP buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Nonidet P-40), and protein complexes were recovered by immunoprecipitation with the CDK2 antiserum. Immunoprecipitates were then split for analysis of protein complexes and of kinase activity exactly as described (Zhang et al., 1994) . For cyclin D1-CDK6, binding reactions were divided into two parts. One was assayed directly for retinoblastoma protein (Rb) kinase activity as described . Complexes present in the other portion of the sample were recovered using a CDK6 antiserum, and complex constituents were analyzed by gel electrophoresis. For cyclin-CDK association and PCNA binding assays, mixtures of baculoviral lysates (as indicated in the figure legends) were incubated for 30 min at 30°C. Reactions were diluted to 250 l with IP buffer, and protein complexes were recovered with CDK2 or p21 antiserum, respectively.
RESULTS

Molecular Analysis of the Human p21
WAF1/CIP1/SDI1 Gene in Primary Breast Carcinomas-To investigate the possible occurrence of p21 mutations in human breast carcinomas, the two coding exons of the p21 gene were directly amplified from genomic DNA extracted from 36 invasive ductal breast tumors and from normal DNA from the same individuals. Direct sequence analysis after asymmetric PCR of the amplified products (496 and 167 base pairs, respectively) revealed sequence alterations in five of the tumor specimens with respect to the wild type sequence reported for the p21 protein (Xiong et al., 1993a; El-Deiry et al., 1993; Harper et al., 1993; Noda et al., 1994) . Four of the p21 alterations were C to A transversions in codon 31 that resulted in replacement of a serine with an arginine (S31R). This sequence alteration has been recently reported as a genetic polymorphism that occurs in approximately 5-10% of the population Shiohara et al., 1994; Li et al., 1995b; Mousses et al., 1995) . The fifth p21 alteration detected in our breast cancer study population was a C to T transition in codon 94 that caused the substitution of a tryptophan residue for an arginine (R94W, Fig. 1A ). This mutation was not detected in normal DNA extracted from the same patient nor was it found in a PCR-restriction fragment length polymorphism screen by digestion with ItaI of the corresponding p21 exon 2 amplified from 50 unrelated individuals (Fig. 1B) . On the basis of these results, it seems that the R94W variant found in this human breast carcinoma is not a polymorphism but a tumor-specific alteration in the p21 protein.
Functional Analysis of the p21 R94W Mutant-To determine whether the R94W mutation altered the biochemical properties of the p21 protein, we generated recombinant baculoviruses that direct the expression of either wild type p21 or mutant p21 R94W proteins as fusions with glutathione S-transferase. Lysates containing 35 S-labeled GST-p21 or GST-p21 R94W were prepared, and the amount of GST-p21 protein present in each lysate was normalized by Western blotting with the p21 antiserum and by direct quantitation of 35 S-labeled proteins. Upon the addition of increasing quantities of GST-p21 or GSTp21 R94W to lysates containing labeled cyclin A-CDK2 complexes, we observed progressive binding of each p21 protein to the enzyme. However, a more than 5-fold greater quantity of mutant GST-p21 was required to achieve kinase inhibition (Fig. 2B) . Similar results were obtained when the recombinant proteins were partially purified from insect cell lysates using glutathione-Sepharose affinity chromatography. In addition, p21 and p21 R94W proteins were produced as polyhistidine fusions and purified from overexpressing bacterial strains as described previously . Again, CDK inhibition required an about 5-10-fold greater quantity of mutant his-p21 than was required of wild type his-p21 protein (data not
Functional Analysis of a p21
R94W Mutantshown). Taken together, these results clearly indicate that recombinant p21 R94W produced in different expression systems is impaired in its ability to inhibit cyclinA-CDK2 kinase. Nevertheless, the possibility that a minor part of the observed impairment in the inhibitory properties of the p21 mutant can be due to an increased dissociation rate of this mutant from the ternary complexes during the kinase assays cannot be definitively ruled out. We also analyzed the possibility that the mutant and wild type p21 proteins could differ in their binding properties to cyclin-CDK complexes. As can be seen in Fig. 2A , no clear differences were detected when low amounts of p21 proteins (up to 10 units) were used. However, additional experiments in which 100 units of p21 R94W were added to lysates, revealed a complete inhibition of the kinase activity (not shown). The absence of a plateau of inhibition at saturating concentrations of p21 mutant strongly suggests that mutation has also affected (albeit slightly) the affinity of the protein for the cyclin-CDK complex. An additional possibility to explain why a slight variation in the amount of bound p21 causes a substantial difference in inhibitory properties, could be related to previous data indicating that two p21 molecules must associate with a cyclin-CDK complex in order for kinase activity to be inhibited (Zhang et al., 1994) . According to this hypothesis, the R94W mutation could allow the first but not the second p21 molecule to bind tightly to the complex, with subsequent alterations in the inhibitory properties of the formed complexes. In any case, it is clear that the present experiments do not allow clear conclusions about whether the R94W mutation primarily effects binding to the cyclin-CDK complex. Additional experiments involving competition assays between wild type and mutant p21 will be required to further clarify this point.
Taking into account that it has been previously described that different cyclin-CDK complexes have different p21 affinities (Xiong et al., 1993a; Harper et al., 1993; Gu et al., 1993) , we then tried to extend the above observed effect of the p21 mutant on cyclin A-CDK2 to other cyclin-CDK complexes. For this purpose, equal quantities of wild type p21 and mutant p21 R94W proteins were added to lysates containing labeled cyclin D1-CDK6 complexes and, the binding and inhibitory properties of both p21 proteins were analyzed as indicated above. As can be seen in Fig. 3A , no clear variations in binding of the wild type and mutant p21 proteins to the enzyme were detected. By contrast, whereas the addition of 10 units of wild type p21 protein substantially inhibited CDK6 kinase, the addition of 20 units of the mutant p21 protein was without effect (Fig. 3B) . In fact, the addition of 50 -100 units of R94W was required to achieve total CDK6 inhibition (data not shown), indicating that as with cyclin A-CDK2, p21
R94W had a reduced ability to inhibit CDK6 kinase. Similar results were obtained with cyclin D-CDK4 and cyclin B-CDC2 complexes. Thus, the effect of the mutation in the activity of p21 against diverse cyclin-CDK enzymes is general and not circumscribed to a specific type of complex.
After these results and considering that it has been reported that p21 may also play a positive role in cell cycle progression
FIG. 1. Identification of an Arg
94 3 Trp mutation in the p21 gene in a human breast carcinoma. A, autoradiograph of a sequencing gel from part of the exon 2 of the p21 gene in tumor tissue (T) or peripheral blood lymphocytes (L) from the same patient. The C to T transition leads to an amino acid substitution R94W. The sequencing reactions were performed on both strands of the PCR products after asymmetric amplifications. Noncoding strand is shown in the figure. B, ItaI digests of the exon 2 PCR product from the same mutated tumor sample (M) and nonmutated samples (N). 10-l portions of the PCR product were digested for 2 h at 37°C with ItaI (Boehringer Manheinm) and then electrophoresed in 2.5% agarose gels and stained with ethidium bromide. Heterozygous mutated sample (M) shows an extra 175-base pair band due to the loss of an ItaI restriction site.
FIG. 2. Analysis of the ability of p21 and p21
R94W to bind and inhibit cyclin A-CDK2. Increasing quantities of GST-p21 or GSTp21 R94W were added to a fixed quantity of insect cell lysate containing active cyclin A-CDK2, and the resulting complexes immunoprecipitated with a CDK2 antibody. Association of GST-p21 and GST-p21 R94W with CDK2 was analyzed directly by electrophoresis of 35 S-labeled proteins (A), and the kinase activity of the complexes was tested using histone H1 as a substrate (B). The amount of p21 protein present in GST-p21 lysates or GST-p21 
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R94W Mutantwhen present at subsaturating concentrations (Zhang et al., 1994) , we examined the possibility that the p21 mutant could have affected its putative positive role on the cell cycle.
To this end, we tested the ability of p21 R94W mutant to promote subunit association by titrating equal amounts of GST-p21 or GST-p21 R94W into a fixed amount of separately expressed cyclin A and CDK2. As shown in Fig. 4 , there was little or no cyclin A present in CDK2 immunoprecipitates if cyclin A and CDK2 were incubated in the absence of either wild type or mutant p21 proteins. However, upon the addition of either wild type or mutant p21 R94W protein to the mixture, association between cyclin A and CDK2 was enhanced about 10-fold (Fig.  4) . Consequently, and because both p21 proteins promoted cyclin-CDK association to a similar degree, any positive role played by p21 in cell cycle control is likely to be unaffected by the R94W mutation.
Finally, and because in addition to functioning as an inhibitor of CDKs, p21 can form an independent complex with PCNA and interfere with its ability to serve as an essential factor for DNA replication Flores-Rozas et al., 1994) , we have also examined the possibility that p21 binding to PCNA was affected as a result of the R94W mutation. To do that, increasing amounts of GST-p21 or GST-p21 R94W were incubated with a fixed amount of PCNA, and the putative complexes formed between both molecules were recovered after immunoprecipitation with a p21 antiserum. As can be seen in Fig. 5 , the wild type and mutant proteins associated with PCNA to a similar extent, indicating that the mutant protein may retain the ability to inhibit replicative DNA synthesis.
DISCUSSION
In this work we have performed a molecular analysis of the p21 WAF1/CIP1/SDI1 gene in a series of 36 primary breast carcinomas with the finding of a single tumor specific mutation.
This mutation results in the substitution of a tryptophan for an arginine residue at position 94 of the amino acid sequence previously determined for this CDK inhibitor. Furthermore, and because the only p21 mutation reported to date was found in a Burkitt's lymphoma cell line (Bhatia et al., 1995) , this work represents to our knowledge the first description of a p21 mutation in a primary tumor.
In an attempt to examine the possible functional consequences of the R94W mutation, we have performed an analysis of the different biochemical properties of the identified p21 mutant, including studies of binding and inhibition of different cyclin-CDK complexes, examination of putative variations in its role as positive regulator of the cell cycle, and finally analysis of potential alterations in its binding properties to PCNA. These functional studies have revealed that the mutant protein is substantially impaired (between 5-and 10-fold) in its ability to inhibit a series of cyclin-CDK complexes, including cyclin A-CDK2, cyclin D1-CDK6, cyclin D-CDK4, and cyclin B-CDC2. Because residue 94 lies outside the minimal extent of the proposed CDK inhibitory domain (residues 1-80, Polyak et al., 1994) , it is possible that this alteration has its effect on the overall structure of p21 rather than on a specific binding site within the protein. In this regard, it should be also noted that the Arg residue at position 94 is absolutely conserved in the amino acid sequence determined for the p21 protein from different strains of mice, including distantly related species (ElDeiry et al., 1993; Huppi et al., 1994) . This observation provides additional support for the potential relevance of this specific residue for the CDK inhibitory role of p21.
In contrast to the observed impairment of the p21 R94W mutant in its CDK-inhibitory ability, this protein was unaltered in FIG. 3 . Analysis of the ability of p21 and p21 R94W to bind and inhibit cyclinD1-CDK6. Increasing quantities of GST-p21 or GSTp21 R94W were added to insect cell lysates containing cyclin D1-CDK6 kinase, and resulting complexes were recovered by immunoprecipitation with a CDK6 antiserum. Complex formation was monitored by electrophoresis of 35 S-labeled proteins (A), and activity of the complexes was tested directly in lysates using GST-Rb as a substrate (B). The amount of p21 protein was normalized as above. The first lane of each panel contained no p21, and subsequent lanes contained 1, 2, 5, 10, or 20 units of protein.
FIG. 4. Analysis of the ability of p21 and p21
R94W to promote association of cyclin A and CDK2. Increasing quantities of GST-p21 or GST-p21 R94W were mixed with a fixed amount of an insect cell lysate containing cyclin A and with a fixed quantity of an insect cell lysate containing CDK2. The resulting complexes were recovered with a CDK2 antibody, and 35 S-labeled proteins present in the immunoprecipitates were visualized following electrophoresis. Each incubation contained 5 l of CDK2 lysate and 5 l of cyclin A lysate. Equal quantities of GST-p21 or GST-p21 R94W were used in equivalent lanes of each panel. Lysates were adjusted to a final volume of 30 l with kinase buffer. Each incubation also contained 1 mM ATP and proceeded for 30 min at 30°C before immunoprecipitation. 
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R94W Mutantits ability to promote cyclin-CDK association, suggesting that the R94W mutation preferentially affected the inhibitory role of p21 while leaving any possible function as a kinase activator intact. Similarly, p21 and p21 R94W were virtually identical in their ability to bind PCNA, and thus the mutant may retain the ability to inhibit replicative DNA synthesis. The finding that PCNA binding properties are not altered in the p21 R94W mutant is consistent with results from different groups demonstrating that the CDK and PCNA inhibitory activities of p21 are functionally independent and reside in separate protein domains (Chen et al., 1995; Luo et al., 1995; Nakanishi et al., 1995; Warbrick et al., 1995) . A more detailed analysis of the p21 structure has shown that the PCNA inhibitory function is localized at the C-terminal domain of the protein, being of particular relevance in this regard the region comprising residues 141-155 (Nakanishi et al., 1995) . The finding that the p21 mutation identified in this work lies outside of the PCNA inhibitory domain provides additional explanation to our observation that p21 R94W has only affected its CDK inhibitory properties without showing any detectable alteration on its ability to bind PCNA. Finally, it should be mentioned that experiments directed to clarify whether the R94W mutation primarily effects binding to the cyclin-CDK complex have not provided definitive answers. Consequently, additional competition experiments between wild type and mutant p21 will be necessary to detect and quantitate the putative differences in binding affinities between both molecules.
In summary, the discovery of a tumor-specific mutation that impairs the ability of p21 to inhibit CDKs suggests that inactivation of p21 may somewhat contribute to neoplastic transformation. However, the results of mutational analysis of this gene in different cancer types appear to indicate that p21 mutations in human tumors will be rare events Shiohara et al., 1994; Li et al., 1995b; Mousses et al., 1995) . Therefore, it is tempting to speculate that loss of its function will be most often a consequence of inactivation of the tumor suppressor p53 rather than the result of genetic alteration in its own structure. In this regard, it should be mentioned that recent studies from different groups have converged in the elucidation of the mechanisms by which this tumor suppressor guards normal cells against genetic damage (see Cox and Lane (1995) for a review). Thus, p53 enforces cell cycle arrest via transcriptional induction of p21 expression Dulic et al., 1994) , elicites apoptosis through induction of the Bax gene (Miyashita and Reed, 1995) , and enhances DNA repair via induction of GADD45 . Therefore, and although loss of the p21 pathway in the p53 response may contribute in some cases to neoplastic transformation, the frequent inactivation of p53 in human cancer must reflect simultaneous loss of multiple regulatory pathways. In fact, and according to recent data (Deng et al., 1995; Brugarolas et al., 1995) , mice lacking p21, despite being defective in G 1 checkpoint control, have not developed spontaneous malignancies during the first 7 months of observation, suggesting that p53-dependent suppression of early tumor formation is independent of p21.
